Mr Moshe Rogosnitzky is Founder and CEO at Drug Rediscovery Group Ltd. An innovator in drug repurposing, he is a named inventor on numerous patents in many therapeutic fields. As a scientist, serial inventor, innovator, thought leader, and researcher, his mission is to create sustainable, self-empowering healthcare solutions and to champion accessible healthcare worldwide. Based in Israel, he helps people to live better lives by discovering new applications for established drugs, through personalized medicine.
As the Founder of Israel’s first personalized medicine consultancy, Adjuvant Medical Solutions, he used highly specific diagnostics to develop patient-centered treatment strategies for those for whom standard treatment protocols had failed.
In 2006 he co-founded the US non-profit organization, MedInsight® Research Institute, which is focused on delivering affordable and effective medical solutions to people everywhere, by sharing research and reviews about off-label drug uses. At MedInsight, he founded LDNscience.org - the largest global educational platform for Low Dose Naltrexone (LDN), which was key in taking a drug from obscurity to over 500,000 users globally, with published research now covering more than 60 chronic diseases.
He is one of the numerous expert physicians, scientists, government agency officials, and nonprofit leaders around the world who believe that solutions to chronic and life-endangering medical problems lie in the rediscovery and repurposing of widely used, low-cost, and clinically proven safe medicines. Real-world drug repurposing is the only sustainable option to prevent and treat current and future health crises such as the COVID-19 epidemic.
As an expert in drug repurposing, he has had the opportunity to share his unique approach at the Israel Ministry of Health, Massachusetts Institute of Technology, and at the Charité Health Summit in Berlin.